Sana Biotechnology (NASDAQ:SANA) Upgraded to Outperform at Citizens Jmp

Sana Biotechnology (NASDAQ:SANA) was upgraded by stock analysts at Citizens Jmp from a “market perform” rating to an “outperform” rating in a research note issued on Tuesday,Finviz reports. The firm presently has a $5.00 price target on the stock. Citizens Jmp’s price objective would indicate a potential upside of 80.51% from the stock’s current price.

A number of other research firms have also recently weighed in on SANA. HC Wainwright raised their price target on Sana Biotechnology from $8.00 to $11.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. Jefferies Financial Group began coverage on Sana Biotechnology in a research note on Friday. They issued a “buy” rating and a $7.00 price target on the stock. Finally, TD Cowen upgraded Sana Biotechnology from a “hold” rating to a “buy” rating in a research note on Wednesday, January 8th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $10.80.

Sana Biotechnology Stock Down 5.5 %

NASDAQ:SANA opened at $2.77 on Tuesday. The stock’s fifty day moving average is $3.05 and its two-hundred day moving average is $3.23. Sana Biotechnology has a 52 week low of $1.52 and a 52 week high of $10.50. The stock has a market capitalization of $618.46 million, a price-to-earnings ratio of -1.98 and a beta of 1.63.

Sana Biotechnology (NASDAQ:SANA) last announced its quarterly earnings data on Thursday, March 20th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.01). On average, sell-side analysts expect that Sana Biotechnology will post -1.16 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Fmr Llc sold 290,912 shares of the firm’s stock in a transaction dated Wednesday, January 8th. The stock was sold at an average price of $6.49, for a total transaction of $1,888,018.88. Following the transaction, the insider now owns 4,541,511 shares of the company’s stock, valued at $29,474,406.39. This trade represents a 6.02 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 31.10% of the company’s stock.

Hedge Funds Weigh In On Sana Biotechnology

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. grew its holdings in shares of Sana Biotechnology by 10.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 47,341 shares of the company’s stock worth $77,000 after buying an additional 4,554 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Sana Biotechnology by 17.9% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 35,196 shares of the company’s stock valued at $146,000 after purchasing an additional 5,338 shares in the last quarter. Teacher Retirement System of Texas boosted its holdings in Sana Biotechnology by 20.3% in the 4th quarter. Teacher Retirement System of Texas now owns 36,797 shares of the company’s stock valued at $60,000 after purchasing an additional 6,209 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Sana Biotechnology by 2.4% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 280,731 shares of the company’s stock valued at $457,000 after purchasing an additional 6,613 shares in the last quarter. Finally, Blue Trust Inc. boosted its holdings in Sana Biotechnology by 51.0% in the 4th quarter. Blue Trust Inc. now owns 19,823 shares of the company’s stock valued at $32,000 after purchasing an additional 6,694 shares in the last quarter. Hedge funds and other institutional investors own 88.23% of the company’s stock.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.